针对细胞内病原体土拉弗朗西斯菌的体液免疫和细胞介导免疫。
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.
作者信息
Kirimanjeswara Girish S, Olmos Sofia, Bakshi Chandra S, Metzger Dennis W
机构信息
Center for Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208, USA.
出版信息
Immunol Rev. 2008 Oct;225:244-55. doi: 10.1111/j.1600-065X.2008.00689.x.
Abstract
Francisella tularensis can cause fatal respiratory tularemia in humans and animals and is increasingly being isolated in the United States and several European countries. The correlates of protective immunity against this intracellular bacterium are not known, and currently there are no licensed vaccines available for human use. Cell-mediated immunity has long been believed to be critical for protection, and the importance of humoral immunity is also now recognized. Furthermore, synergy between antibodies, T cell-derived cytokines, and phagocytes appears to be critical to achieve sterilizing immunity against F. tularensis. Thus, novel vaccine approaches should be designed to induce robust antibody and cell-mediated immune responses to this pathogen.
摘要
土拉弗朗西斯菌可导致人类和动物发生致命的呼吸道兔热病，在美国和几个欧洲国家越来越多地被分离出来。针对这种细胞内细菌的保护性免疫相关因素尚不清楚，目前尚无获批用于人类的疫苗。长期以来，细胞介导的免疫一直被认为对保护至关重要，体液免疫的重要性现在也得到了认可。此外，抗体、T细胞衍生的细胞因子和吞噬细胞之间的协同作用似乎对于实现针对土拉弗朗西斯菌的杀菌免疫至关重要。因此，应设计新的疫苗方法来诱导针对这种病原体的强大抗体和细胞介导的免疫反应。
相似文献
1
Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.针对细胞内病原体土拉弗朗西斯菌的体液免疫和细胞介导免疫。
Immunol Rev. 2008 Oct;225:244-55. doi: 10.1111/j.1600-065X.2008.00689.x.
2
Adaptive Immunity to and Considerations for Vaccine Development.适应性免疫与疫苗开发的考虑因素。
Front Cell Infect Microbiol. 2018 Apr 6;8:115. doi: 10.3389/fcimb.2018.00115. eCollection 2018.
3
Nature of protective immunity to Francisella tularensis.针对土拉弗朗西斯菌的保护性免疫的本质。
Rev Infect Dis. 1989 May-Jun;11(3):440-51.
4
Detrimental Influence of Alveolar Macrophages on Protective Humoral Immunity during Francisella tularensis SchuS4 Pulmonary Infection.肺泡巨噬细胞对土拉弗朗西斯菌肺部感染期间保护性体液免疫的有害影响。
Infect Immun. 2018 Mar 22;86(4). doi: 10.1128/IAI.00787-17. Print 2018 Apr.
5
Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.单磷酰脂质A通过增强体液免疫和细胞免疫来提高土拉热弗朗西斯菌LVS-阳离子纳米颗粒亚单位疫苗对土拉热弗朗西斯菌Schu S4攻击的效力。
Clin Vaccine Immunol. 2017 Mar 6;24(3). doi: 10.1128/CVI.00574-16. Print 2017 Mar.
6
Cellular and humoral immunity are synergistic in protection against types A and B Francisella tularensis.细胞免疫和体液免疫在抵御A型和B型土拉弗朗西斯菌方面具有协同作用。
Vaccine. 2009 Jan 22;27(4):597-605. doi: 10.1016/j.vaccine.2008.10.079. Epub 2008 Nov 18.
7
Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection.自然感染25年后，针对胞内细菌土拉热弗朗西斯菌的细胞介导免疫持续存在而体液免疫下降。
J Infect Dis. 1994 Jul;170(1):110-4. doi: 10.1093/infdis/170.1.110.
8
Aim2 and Nlrp3 Are Dispensable for Vaccine-Induced Immunity against Francisella tularensis Live Vaccine Strain.目的 2 和 Nlrp3 对于对抗弗朗西斯氏菌活疫苗株的疫苗诱导免疫是可有可无的。
Infect Immun. 2021 Jun 16;89(7):e0013421. doi: 10.1128/IAI.00134-21.
9
An Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy.一种共培养小鼠模型证明了疫苗介导的对SCHU S4的有效控制，并确定一氧化氮为疗效预测指标。
Front Cell Infect Microbiol. 2016 Nov 25;6:152. doi: 10.3389/fcimb.2016.00152. eCollection 2016.
10
Identification of a live attenuated vaccine candidate for tularemia prophylaxis.鉴定一种用于土拉菌病预防的减毒活疫苗候选株。
PLoS One. 2013 Apr 17;8(4):e61539. doi: 10.1371/journal.pone.0061539. Print 2013.
引用本文的文献
1
The immune response to .对……的免疫反应。 （你提供的原文不完整，以上是根据现有内容翻译的）
Front Microbiol. 2025 Apr 25;16:1549343. doi: 10.3389/fmicb.2025.1549343. eCollection 2025.
2
A novel method of Francisella infection of epithelial cells using HeLa cells expressing fc gamma receptor.一种利用表达 fcγ受体的 HeLa 细胞感染上皮细胞的新型弗朗西斯菌感染方法。
BMC Infect Dis. 2024 Oct 17;24(1):1171. doi: 10.1186/s12879-024-10083-y.
3
Current vaccine strategies and novel approaches to combatting Francisella infection.当前疫苗策略和新型方法对抗弗朗西斯菌感染。
Vaccine. 2024 Apr 2;42(9):2171-2180. doi: 10.1016/j.vaccine.2024.02.086. Epub 2024 Mar 8.
4
The rLVS Δ/ vaccine provides potent protection in Fischer rats against inhalational tularemia caused by various virulent strains.rLVSΔ/疫苗为费希尔大鼠提供了针对各种强毒菌株吸入性土拉菌病的有力保护。
Hum Vaccin Immunother. 2023 Dec 15;19(3):2277083. doi: 10.1080/21645515.2023.2277083. Epub 2023 Nov 17.
5
Modified activities of macrophages' deubiquitinating enzymes after infection.感染后巨噬细胞去泛素化酶活性的改变。
Front Immunol. 2023 Sep 29;14:1252827. doi: 10.3389/fimmu.2023.1252827. eCollection 2023.
6
Kinetics of the serological response up to one year after tularemia.一年内土拉菌病血清学反应动力学。
Front Cell Infect Microbiol. 2023 Jan 6;12:1072703. doi: 10.3389/fcimb.2022.1072703. eCollection 2022.
7
Controlled human infectious models, a path forward in uncovering immunological correlates of protection: Lessons from enteric fevers studies.受控人类感染模型：揭示保护性免疫相关因素的前进道路——来自肠热病研究的经验教训
Front Microbiol. 2022 Sep 20;13:983403. doi: 10.3389/fmicb.2022.983403. eCollection 2022.
8
and Antibodies.以及抗体。
Microorganisms. 2021 Oct 12;9(10):2136. doi: 10.3390/microorganisms9102136.
9
Critical role of IL-25-ILC2-IL-5 axis in the production of anti-Francisella LPS IgM by B1 B cells.IL-25-ILC2-IL-5 轴在 B1 B 细胞产生抗弗朗西斯氏菌 LPS IgM 中的关键作用。
PLoS Pathog. 2021 Aug 27;17(8):e1009905. doi: 10.1371/journal.ppat.1009905. eCollection 2021 Aug.
10
Differential Immune Response Following Intranasal and Intradermal Infection with Implications for Vaccine Development.鼻内和皮内感染后的差异免疫反应及其对疫苗开发的影响。
Microorganisms. 2021 Apr 30;9(5):973. doi: 10.3390/microorganisms9050973.
本文引用的文献
1
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis.利用Fc受体作为针对细胞内细菌土拉弗朗西斯菌的黏膜疫苗策略。
J Immunol. 2008 Apr 15;180(8):5548-57. doi: 10.4049/jimmunol.180.8.5548.
2
Molecular immunology of experimental primary tularemia in mice infected by respiratory or intradermal routes with type A Francisella tularensis.用A 型土拉热弗朗西斯菌经呼吸道或皮内途径感染小鼠的实验性原发性土拉菌病的分子免疫学
Mol Immunol. 2008 May;45(10):2962-9. doi: 10.1016/j.molimm.2008.01.022. Epub 2008 Mar 5.
3
IFNgamma enhances IL-23 production during Francisella infection of human monocytes.在人单核细胞感染弗朗西斯菌期间，γ干扰素增强白细胞介素-23的产生。
FEBS Lett. 2008 Apr 2;582(7):1044-8. doi: 10.1016/j.febslet.2008.02.058. Epub 2008 Mar 3.
4
A Francisella mutant in lipid A carbohydrate modification elicits protective immunity.脂多糖碳水化合物修饰的弗朗西斯菌突变体引发保护性免疫。
PLoS Pathog. 2008 Feb 8;4(2):e24. doi: 10.1371/journal.ppat.0040024.
5
NK cells and gamma interferon coordinate the formation and function of hepatic granulomas in mice infected with the Francisella tularensis live vaccine strain.自然杀伤细胞和γ干扰素协同调节感染土拉弗朗西斯菌活疫苗株的小鼠肝脏肉芽肿的形成和功能。
Infect Immun. 2008 Apr;76(4):1379-89. doi: 10.1128/IAI.00745-07. Epub 2008 Jan 28.
6
The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge.肺部感染后小鼠血浆中存在传染性细胞外土拉热弗朗西斯菌新凶手亚种。
Eur J Clin Microbiol Infect Dis. 2008 Apr;27(4):323-5. doi: 10.1007/s10096-007-0434-x. Epub 2007 Dec 18.
7
Persistence of category A select agents in the environment.环境中A类特定生物制剂的持久性。
Appl Environ Microbiol. 2008 Feb;74(3):555-63. doi: 10.1128/AEM.02167-07. Epub 2007 Dec 7.
8
Differential requirements by CD4+ and CD8+ T cells for soluble and membrane TNF in control of Francisella tularensis live vaccine strain intramacrophage growth.CD4+和CD8+ T细胞对可溶性和膜结合型肿瘤坏死因子在控制土拉弗朗西斯菌活疫苗株巨噬细胞内生长方面的不同需求。
J Immunol. 2007 Dec 1;179(11):7709-19. doi: 10.4049/jimmunol.179.11.7709.
9
Vaccine Prophylaxis against Tularemia in Man.人类兔热病的疫苗预防
Am J Public Health Nations Health. 1942 Oct;32(10):1131-45. doi: 10.2105/ajph.32.10.1131.
10
Dendritic cells: understanding immunogenicity.树突状细胞：理解免疫原性。
Eur J Immunol. 2007 Nov;37 Suppl 1:S53-60. doi: 10.1002/eji.200737400.
Zotero 插件